Drug discontinuation: Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution (PLENVU)
FDA lists 1 presentation as To Be Discontinued. Companies: Salix Pharmaceuticals, a division of Bausch Health US, LLC.
- Published by source
- 2026-08-13
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Salix Pharmaceuticals, a division of Bausch Health US, LLC
- Products
- Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution PLENVU
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- A business decision was made to discontinue manufacture of the drug.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-08-13
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #902 | new | 2026-10-22 | 552e0683a393…850f9a | 9d2bc40269d7…4f523f |
Chain head: #1076 8ad5adc30b9b…88ce20